Page 31 - 2022-27-中国全科医学

·3356· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

American Gastroenterological Association Institute technical review ［16］RUTGEERTS P，GASINK C，CHAN D，et al. Efficacy of
on the use of thiopurines，methotrexate，and anti-TNF-α biologic ustekinumab for inducing endoscopic healing in patients with Crohn's
drugs for the induction and maintenance of remission in inflammatory disease［J］. Gastroenterology，2018，155（4）：1045-1058.
Crohn's disease［J］. Gastroenterology，2013，145（6）： 1464- DOI：10.1053/j.gastro.2018.06.035.
1478.e1-5. DOI：10.1053/j.gastro.2013.10.046. ［17］LI K，FRIEDMAN J R，CHAN D，et al. Effects of ustekinumab
［4］LICHTENSTEIN G R，RUTGEERTS P，SANDBORN W J， on histologic disease activity in patients with Crohn's disease［J］.
et al. A pooled analysis of infections，malignancy，and mortality Gastroenterology，2019，157（4）：1019-1031.e7. DOI：
in infliximab- and immunomodulator-treated adult patients with 10.1053/j.gastro.2019.06.037.
inflammatory bowel disease［J］. Am J Gastroenterol，2012，107（7）： ［18］SANDBORN W J，REBUCK R，WANG Y H，et al. Five-year
1051-1063. DOI：10.1038/ajg.2012.89. efficacy and safety of ustekinumab treatment in Crohn's disease：the
［5］LEE J W，CHOI C H，PARK J H，et al. Clinical features of active IM-UNITI trial［J］. Clin Gastroenterol Hepatol，2022，20（3）：
tuberculosis that developed during anti-tumor necrosis factor therapy 578-590.e4. DOI：10.1016/j.cgh.2021.02.025.
in patients with inflammatory bowel disease［J］. Intest Res， ［19］HANAUER S B，SANDBORN W J，FEAGAN B G，et al. IM-
2016，14（2）：146-151. DOI：10.5217/ir.2016.14.2.146. UNITI：three-year efficacy，safety，and immunogenicity of
［6］MOLODECKY N A，SOON I S，RABI D M，et al. Increasing ustekinumab treatment of Crohn's disease［J］. J Crohns Colitis，
incidence and prevalence of the inflammatory bowel diseases with 2020，14（1）： 23-32. DOI：10.1093/ecco-jcc/jjz110.
time，based on systematic review［J］. Gastroenterology，2012，142（1）： ［20］BIEMANS V B C，VAN DER MEULEN-DE JONG A E，VAN
46-54.e42；quize30. DOI：10.1053/j.gastro.2011.10.001. DER WOUDE C J，et al. Ustekinumab for Crohn's disease：results
［7］LOVASZ B D，GOLOVICS P A，VEGH Z，et al. New trends in of the ICC registry，a nationwide prospective observational cohort
inflammatory bowel disease epidemiology and disease course in study［J］. J Crohns Colitis，2020，14（1）：33-45. DOI：
Eastern Europe［J］. Dig Liver Dis，2013，45（4）：269-276. 10.1093/ecco-jcc/jjz119.
DOI：10.1016/j.dld.2012.08.020. ［21］GONCZI L，SZANTO K，FARKAS K，et al. Clinical efficacy，
［8］TURNER D，RICCIUTO A，LEWIS A，et al. STRIDE- Ⅱ： drug sustainability and serum drug levels in Crohn's disease patients
an update on the selecting therapeutic targets in inflammatory bowel treated with ustekinumab-A prospective，multicenter cohort from
disease（STRIDE）initiative of the international organization for the Hungary［J］. Dig Liver Dis， 2022，54（2）： 207-213. DOI：
study of IBD（IOIBD）： determining therapeutic goals for treat-to- 10.1016/j.dld.2021.07.008.
target strategies in IBD［J］. Gastroenterology，2021，160（5）： ［22］ROGERIO P，JULIO C，LILIANA C，et al. P008 long-term
1570-1583. DOI：10.1053/j.gastro.2020.12.031. effectiveness and safety of ustekinumab for the treatment of crohn's
［9］BILLIOUD V，SANDBORN W J，PEYRIN-BIROULET L. Loss disease：a Brazilian multicentre real-world study［J］. Am J
of response and need for adalimumab dose intensification in Crohn's Gastroenterol，2020，115（Suppl 1）：S2. DOI：10.14309/01.
disease：a systematic review［J］. Am J Gastroenterol，2011， ajg.0000722828.45880.db.
106（4）： 674-684. DOI：10.1038/ajg.2011.60. ［23］姚嘉茵，宋孝美，余乔，等 . 乌司奴单克隆抗体治疗难治
［10］GISBERT J P，PANÉS J. Loss of response and requirement of 性克罗恩病的短期疗效分析：一项多中心回顾性观察性研
infliximab dose intensification in Crohn's disease： a review［J］. 究［J］. 中华炎性肠病杂志，2021，5（2）：151-155. DOI：
Am J Gastroenterol，2009，104（3）：760-767. DOI： 10.3760/cma.j.cn101480-20210326-00025.
10.1038/ajg.2008.88. YAO J Y，SONG X M，YU Q，et al. Analysis of the short-
［11］宋阿倩，周秀彦 . 乌司奴单抗在治疗克罗恩病中的作用机制［J］. term efficacy of ustekinumab for intractable Crohn's disease：a
胃肠病学和肝病学杂志，2021，30（8）： 946-949. multicenter retrospective observational study［J］. Chinese Journal
SONG A Q，ZHOU X Y. Mechanism of Ustekinumab in of Inflammatory Bowel Diseases，2021，5（2）： 151-155.
the treatment of Crohn's disease［J］. Chinese Journal of DOI：10.3760/cma.j.cn101480-20210326-00025.
Gastroenterology and Hepatology，2021，30（8）： 946-949. ［24］HARRIS K A，HORST S，GADANI A，et al. Patients
［12］MOSCHEN A R，TILG H，RAINE T. IL-12，IL-23 and IL- with refractory Crohn's disease successfully treated with
17 in IBD：immunobiology and therapeutic targeting［J］. Nat ustekinumab［J］. Inflamm Bowel Dis，2016，22（2）：397-
Rev Gastroenterol Hepatol，2019，16（3）： 185-196. DOI： 401. DOI：10.1097/MIB.0000000000000624.
10.1038/s41575-018-0084-8. ［25］STRAATMIJER T，BIEMANS V B C，HOENTJEN F，et al.
［13］NEURATH M F. IL-23 in inflammatory bowel diseases and colon Ustekinuma b for Crohn's disease：two-year results of the initiative
cancer［J］. Cytokine Growth Factor Rev，2019，45：1-8. DOI： on crohn and colitis（ICC） registry，a nationwide prospective
10.1016/j.cytogfr.2018.12.002. observational cohort study［J］. J Crohns Colitis，2021，15（11）：
［14］DEEPAK P，SANDBORN W J. Ustekinumab and anti- 1920-1930. DOI：10.1093/ecco-jcc/jjab081.
interleukin-23 agents in Crohn's disease［J］. Gastroenterol ［26］BAR-GIL SHITRIT A，BEN-YA ACOV A，SITERMAN M，
Clin North Am，2017，46（3）：603-626. DOI：10.1016/j. et al. Safety and effectiveness of ustekinumab for induction of
gtc.2017.05.013. remission in patients with Crohn's disease：a multicenter Israeli
［15］FEAGAN B G，SANDBORN W J，GASINK C，et al. Ustekinumab study［J］. United European Gastroenterol J，2020，8（4）：
as induction and maintenance therapy for Crohn's disease［J］. N 418-424. DOI：10.1177/2050640620902956.
Engl J Med，2016，375（20）：1946-1960. ［27］BIEMANS V B C，VAN DER WOUDE C J，DIJKSTRA G，